The role of GSK3 in Alzheimer disease

Mutations in app, ps-1 and ps-2 genes result in the appearance of Familial Alzheimer disease (FAD). Although, in many cases, those mutations result in an increase of the amount of beta amyloid peptide, there is not a clear correlation between that amount and the time of the onset of the disease. Thus, other factors may explain how mutations in those genes result in the appearance of neurodegeneration. In this minireview we propose that GSK3 could be one of those factors.

[1]  R. Hen,et al.  Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. , 2001, The EMBO journal.

[2]  Christina A. Wilson,et al.  GSK-3α regulates production of Alzheimer's disease amyloid-β peptides , 2003, Nature.

[3]  Bradley T. Hyman,et al.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.

[4]  A. Myers,et al.  Common genetic variation within the Low-Density Lipoprotein Receptor-Related Protein 6 and late-onset Alzheimer's disease , 2007, Proceedings of the National Academy of Sciences.

[5]  J. Lucas,et al.  Cooexpression of FTDP-17 tau and GSK-3β in transgenic mice induce tau polymerization and neurodegeneration , 2006, Neurobiology of Aging.

[6]  A. Delacourte,et al.  The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease , 1999, Neurology.

[7]  Jörg Stappert,et al.  β‐catenin is a target for the ubiquitin–proteasome pathway , 1997 .

[8]  M. Leissring.  The AβCs of Aβ-cleaving Proteases* , 2008, Journal of Biological Chemistry.

[9]  D. Selkoe,et al.  Soluble Aβ Inhibits Specific Signal Transduction Cascades Common to the Insulin Receptor Pathway* , 2007, Journal of Biological Chemistry.

[10]  C. Masters,et al.  Degradation of the Alzheimer Disease Amyloid β-Peptide by Metal-dependent Up-regulation of Metalloprotease Activity* , 2006, Journal of Biological Chemistry.

[11]  E. R. Andersson,et al.  The extracellular domain of Lrp5/6 inhibits noncanonical Wnt signaling in vivo. , 2008, Molecular biology of the cell.

[12]  Khadija Iqbal,et al.  Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Yoichi Kato,et al.  LDL-receptor-related proteins in Wnt signal transduction , 2000, Nature.

[14]  D. Price,et al.  Mutant genes in familial Alzheimer's disease and transgenic models. , 1998, Annual review of neuroscience.

[15]  A. Alzheimer.  Uber eine eigenartige Erkrankung der Hirnrinde , 1907 .

[16]  R Kemler,et al.  beta-catenin is a target for the ubiquitin-proteasome pathway. , 1997, The EMBO journal.

[17]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[18]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[19]  D. Geschwind,et al.  Association of GSK 3 B With Alzheimer Disease and Frontotemporal Dementia , 2008 .

[20]  Lin Xie,et al.  Increased hippocampal neurogenesis in Alzheimer's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Lucas,et al.  Full Reversal of Alzheimer's Disease-Like Phenotype in a Mouse Model with Conditional Overexpression of Glycogen Synthase Kinase-3 , 2006, The Journal of Neuroscience.

[22]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[23]  Ethan Lee,et al.  LRP6 transduces a canonical Wnt signal independently of Axin degradation by inhibiting GSK3's phosphorylation of β-catenin , 2008, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Ávila,et al.  Extracellular tau is toxic to neuronal cells , 2006, FEBS letters.

[25]  René Hen,et al.  Decreased nuclear β‐catenin, tau hyperphosphorylation and neurodegeneration in GSK‐3β conditional transgenic mice , 2001 .

[26]  J. Lucas,et al.  N-terminal Cleavage of GSK-3 by Calpain , 2007, Journal of Biological Chemistry.

[27]  F. Gage,et al.  Mechanisms and Functional Implications of Adult Neurogenesis , 2008, Cell.

[28]  J. Lucas,et al.  Spatial learning deficit in transgenic mice that conditionally over‐express GSK‐3β in the brain but do not form tau filaments , 2002, Journal of neurochemistry.

[29]  L. Baki,et al.  PS1 activates PI3K thus inhibiting GSK‐3 activity and tau overphosphorylation: effects of FAD mutations , 2004, The EMBO journal.

[30]  Chris G. Parsons,et al.  Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse , 2007, Neuropharmacology.

[31]  M. Mercken,et al.  Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[32]  L. Juliano,et al.  Amyloid-β Binds to the Extracellular Cysteine-rich Domain of Frizzled and Inhibits Wnt/β-Catenin Signaling* , 2008, Journal of Biological Chemistry.

[33]  Jesús Avila,et al.  The role of glycogen synthase kinase 3 in the early stages of Alzheimers’ disease , 2008, FEBS letters.

[34]  D. Geschwind,et al.  Association of GSK3B with Alzheimer disease and frontotemporal dementia. , 2008, Archives of neurology.

[35]  J. Ávila,et al.  Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells , 2008, Molecular and Cellular Neuroscience.

[36]  J. García-Verdugo,et al.  Cell types, lineage, and architecture of the germinal zone in the adult dentate gyrus , 2004, The Journal of comparative neurology.

[37]  Christina A. Wilson,et al.  GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. , 2003, Nature.